Abstract
Dose-limiting toxicities are ubiquitous to cancer-directed therapy, presenting with severity to a degree that necessitates therapy de-escalation, pause, or discontinuation. To date, there is incredible limited understanding if these therapy de-escalations present risk for survival by limiting delivery of intensive therapy, or if they indicate physiologic susceptibility and are a favorable prognostic indicator. Mucositis is an excellent illustration of the current paradox of dose-limiting toxicities—it has existed alongside therapy for eight decades, but despite its presence, there is an incomplete understanding of how it develops, why it varies between oncologic populations, and if it relates to cancer survival. Rigorous methodologic approaches in symptom science holds potential to better understand mucositis, to determine if it is a marker of response or threat, and evaluate if it holds potential to guide therapy delivery.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Collins M, Wilhelm M, Conyers R et al (2013) Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol 31(18):2303–2312. https://doi.org/10.1200/jco.2012.43.8598
Fanning SR, Rybicki L, Kalaycio M et al (2006) Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies. Br J Haematol 135(3):374–381. https://doi.org/10.1111/j.1365-2141.2006.06323.x
Nageswara Rao AA, Wallace DJ, Billups C, Boyett JM, Gajjar A, Packer RJ (2014) Cumulative cisplatin dose is not associated with event-free or overall survival in children with newly diagnosed average-risk medulloblastoma treated with cisplatin based adjuvant chemotherapy: report from the Children’s Oncology Group. Pediatr Blood Cancer 61(1):102–106. https://doi.org/10.1002/pbc.24670
McTiernan A, Jinks RC, Sydes MR et al (2012) Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup. Eur J Cancer 48(5):703–712. https://doi.org/10.1016/j.ejca.2011.09.012
Wong HH, Halford S (2015) Dose-limiting toxicity and maximum tolerated dose: still fit for purpose? Lancet Oncol 16(13):1287–1288. https://doi.org/10.1016/S1470-2045(15)00248-X
Fraisse J, Dinart D, Tosi D, Bellera C, Mollevi C (2021) Optimal biological dose: a systematic review in cancer phase I clinical trials. BMC Cancer 21(1):60. https://doi.org/10.1186/s12885-021-07782-z
Miller TP, Marx MZ, Henchen C et al (2022) Challenges and barriers to adverse event reporting in clinical trials: a Children’s Oncology Group report. J Patient Saf 18(3):e672–e679. https://doi.org/10.1097/pts.0000000000000911
Author information
Authors and Affiliations
Contributions
Dr. Thornton and Dr. Orgel devised the topic of this work and both equally contributed to the writing of this manuscript. Both authors have reviewed the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Thornton, C.P., Orgel, E. Dose-limiting mucositis: friend or foe?. Support Care Cancer 31, 617 (2023). https://doi.org/10.1007/s00520-023-08101-x
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00520-023-08101-x